Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — H1 2024 Earnings Presentation
22 slides from Burjeel's earnings presentation, August 2024
Slide 1: Q2 & H1 2024 Leading Super-Specialty Healthcare Provider in MENA
August 2024 Q2 & H1 2024 Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: H1 2024 Highlights
H1 2024 Highlights Leading Super-Specialty Healthcare Provider in MENA
Slide 4: H1'24 Highlights
H1’24 Highlights Financial highlights Recent business developments Leading Health Tech Evolution Revenue AED 2,387m Launched IMed Technologies to create innovative AI-based solutions and foster collaboration with global healthcare 10.4% YoY stakeholders, further improving patient experience, provide
Slide 5: Super-Specialty Care Offering Driving Patient Yields
Super-Specialty Care Offering Driving Patient Yields Recent medical milestones across key complex specialties Super-specialty care performance… …drives patient yield Liver transplants Liver transplants 10 Since inception in Apr’24 AED 700,000 – 1,000,000 Fetal surgeries Fetal surgeries 19 AED 400,00
Slide 6: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in MENA
Slide 7: Accelerated Patient Footfall Growth On the Back of Continued Market Penetration
Accelerated Patient Footfall Growth On the Back of Continued Market Penetration Group inpatient footfall, k Group outpatient footfall, k % bed occupancy % OP utilisation 60% 65% 60% 64% 72% 69% 72% 69% • The Group achieved strong inpatient footfall • Outpatient footfall growth in Q2’24 growth in Q2‘
Slide 8: Sustainable Revenue Growth Across Segments Along with Investments in Future Patient Growth
Sustainable Revenue Growth Across Segments Along with Investments in Future Patient Growth Group Revenue, AED m Group EBITDA (ex-one-offs1), AED m YoY EBITDA margin YoY • The Group delivered sustainable top-line (ex-one-offs) • Group-level EBITDA ex-one-offs declined 1,182 +9.7% growth in Q2’24, dri
Slide 9: Well-Invested Burjeel Medical City Sets to Drive High-Yield Patient Growth & Margin Expansion
Well-Invested Burjeel Medical City Sets to Drive High-Yield Patient Growth & Margin Expansion Total patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy % EBITDA margin 46% 59% 44% 57% 13.2% 16.6% 13.8% 16.2% +20.8% +26.5% 574 +41.2% 246 475 93 194 +19.7% +50.5% 66 +29.6% 291 123 243 48 95 32
Slide 10: Ongoing Investments in Oncology & Super-Specialty Expansion to Unlock Significant Growth Potential
Ongoing Investments in Oncology & Super-Specialty Expansion to Unlock Significant Growth Potential Group OPEX breakdown,1 as % of revenue Group EBITDA analysis, AED m % EBITDA margin 79.9% 81.9% 79.0% 80.3% 21.6% 20.0% 17.9% 8.2% 9.8% 9.2% YoY 9.4% 1.6% 2.0% 1.9% YoY 1.6% +225 (88) +2.2% (8.7%) 24.6
Slide 11: Free Cash Flow & Net Profit Performance
Free Cash Flow & Net Profit Performance Free cash flow,1 AED m Net profit analysis, AED m % FCF conversion2 % Net profit margin 64% 42% 51% 50% 54% 10.4% 10.0% 7.1% 523 +225 (208) 497 YoY +5.9% 366 YoY (24.8%) 225 (6) +3 238 (41) 258 235 (10) (18) 169 2021 2022 2023 H1’23 H1’24 Q1 '23 H1’23 Revenue
Slide 12: Maintaining a Robust Balance Sheet
Maintaining a Robust Balance Sheet AED m FY 2022 FY 2023 H1 2024 Debt maturity as of 30 June 2024 Bank balances and cash 150 170 165 Interest-bearing loans and borrowings 1,261 1,164 1,168 252 227 Bank overdrafts – – – Bank debt1 1,261 1,164 1,168 159 152 131 140 Net debt 1,111 994 1,003 107 Lease l
Slide 13: Guidance
Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 14: H2'24 Business Initiatives
H2’24 Business Initiatives Key management focus Planned business initiatives • Open 3 Burjeel medical facilities in Abu Dhabi: medical center with urgent care in Gayathi, primary care & mental health center in Al Falah and primary Ongoing Expansion in UAE & KSA care center in Saadiyat • Expand Physi
Slide 15: Guidance Reiterated
Guidance Reiterated FY 2024 Mid-term (2025-2027) • UAE Medical center: +1 & Day Surgery centers: +2 • UAE Hospital: +1 Expansion • UAE additional beds: +32 • KSA Specialized Day Surgery centers: +2 • KSA PhysioTherabia centers: +26 • KSA PhysioTherabia centers: +30 • Group revenue growth to normaliz
Slide 16: Q&A Appendix
Q&A Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 17: Business model
1 2 Business 1 Differentiating capabilities model • Level I & II Trauma Center • Centralised Lab Serving all • Level III Tertiary NICU • Nuclear Medicine socio-economic • Physio & Rehab Care • Department of Thalassemia groups • Intraoperative MRI • Advanced Center for Research • Da Vinci Xi robotic
Slide 18: Expanding Our UAE Healthcare Infrastructure
Expanding Our UAE Healthcare Infrastructure Launch of 1 hospital, In 2024-2025, the planned launch of one hospital, two day surgery centers and one medical 2 day surgery centers center will enable the Group to tap into new markets, attract more patients and release hospital utilization capacity for
Slide 19: PhysioTherabia – Entering High Potential KSA Market
PhysioTherabia – Entering High Potential KSA Market Highly attractive entry proposition Launched first premier physiotherapy centers 60 + Physical therapy, rehabilitation and wellness centers in 12 KSA cities in a joint venture (50:50) with Leejam Company 22 centers launched PhysioTherabia centers u
Slide 20: Specialized Day Surgery Centers – Disruptive Innovation in Saudi Healthcare Market
Specialized Day Surgery Centers – Disruptive Innovation in Saudi Healthcare Market Strong rationale for expansion in KSA Compelling opportunity to build • Promising macro and demographic trends innovative healthcare proposition in KSA o GDP growth of c.5.5% p.a. o Riyadh's population forecast to dou
Slide 21: Group & Segment Summary
Group & Segment Summary Group financial summary Segmental financial summary2 AED millions Q2’24 Q2’23 H1’24 H1‘23 AED millions Q2’24 Q2’23 H1’24 H1‘23 Revenue 1,182 1,077 2,387 2,162 Revenue 1,182 1,077 2,387 2,162 Inventories consumed (301) (265) (605) (517) Hospitals3 1,036 960 2,095 1,917 Doctors
Slide 22: Investor Relations
Investor Relations August 2024 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website